Single Agent Rituximab Active in Nodular Lymphocyte Predominant Hodgkin Lymphoma - a podcast by American Society of Clinical Oncology (ASCO)

from 2014-02-10T19:21:27

:: ::

This podcast describes the recent experience of single agent rituximab as management for newly diagnosed and relapsed nodular lymphocyte predominant Hodgkin lymphoma. The podcast includes a summary of the trial and discussion of the implications of the findings that rituximab has activity in both the upfront and relapsed setting.